Abstract
Objective
Our previous study suggested involvement of alternative pathway activation of complement in ANCA-positive pauci-immune crescentic glomerulonephritis (CrGN). This study was to investigate the evidence of complement activation in renal biopsy specimens of patients with ANCA-negative pauci-immune CrGN.
Methods
Renal biopsy specimens from 12 patients with ANCA-negative pauci-immune CrGN were used to detect the staining of membrane attack complex (MAC), C3d, C4d, mannose-binding lectin (MBL), factor B by immunohistochemistry, and/or immunofluorescence. Renal tissue from eight patients with minimal change disease (MCD) and renal tissue obtained from a normal kidney and the normal parts of a nephrectomized kidney due to renal carcinoma was used as disease and normal controls, respectively.
Results
MAC and C3d could be detected in the active renal lesions of cellular crescents in each of the 12 ANCA-negative CrGN patients but not or scarcely detected in patients with MCD and in normal renal tissue. The deposition of other complement components in the 12 patients was heterogeneous. Although none of them had C1q staining, eight of the 12 were C4d positive and six out of the eight were MBL positive. The remaining four only had evidence of the alternative pathway activation by positive staining of C3d, factor B, and MAC. The staining intensity of C4d and MBL was much higher in dialysis-dependent patients than that in dialysis-independent patients.
Conclusion
Complement activation was involved in renal damage of human ANCA-negative pauci-immune CrGN but with heterogeneous activation pathways. Positive staining of C4d and MBL might be associated with poor renal outcome.
Similar content being viewed by others
References
Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63:1164–77.
Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol. 1997;8:314–22.
Harris AA, Falk RJ, Jennette JC. Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. Am J Kidney Dis. 1998;32:179–84.
Short AK, Esnault VL, Lockwood CM. Anti-neutrophil cytoplasmic antibodies and anti-glomerular basement membrane antibodies: Two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis. Am J Kidney Dis. 1995;26:439–45.
Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–63.
Xiao H, Schreiber A, Heeringa P. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170:52–64.
Huugen D, Esch AV, Xiao H, Peutz-kootstra CJ, Buuman WA, Tervaert JW, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71:646–54.
Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20:289–98.
Chen M, Xing GQ, Yu F, Liu G, Zhao MH. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant. 2009;24:1247–52.
Xing GQ, Chen M, Liu G, Heeringa P, Zhang JJ, Zheng X. E J, Kallenberg CG, Zhao MH. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol. 2009;29:282–91.
Hedger N, Stevens J, Drey N, Walker S, Roderick P. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol Dial Transplant. 2000;15:1593–99.
Hung PH, Chiu YL, Lin WC, Chiang WC, Chen YM, Lin SL, et al. Poor renal outcome of antineutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis in Taiwanese. J Formos Med Assoc. 2006;105:804–12.
Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY. Antineutrophil cytoplasmic autoantibody negative pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol. 2007;18:599–605.
Zhao MH, Lockwood CM. A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods. 1996;197:121–30.
Sacks SH, Zhou W. New boundaries for complement in renal disease. J Am Soc Nephrol. 2008;19:1865–69.
Shi XY, Hou FF, Niu HX, Wang GB, Xie D, Guo ZJ, et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology. 2008;149:1829–39.
Jennette JC, Thomas DB. Pauci-immune and antineutrophil cytoplasmic autoantibody associated crescentic glomerulonephritis and vasculitis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Hepinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 644.
Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004;65:2145–52.
Neumann I, Regele H, Kain R, Birck R, Meis FT. Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis. Nephrol Dial Transplant. 2003;18:524–31.
Yu F, Chen M, Gao Y, Wang SX, Zou WZ, Zhao MH, et al. Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am J Kidney Dis. 2007;49:607–14.
Chen M, Kallenberg CGM, Zhao MH. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol. 2009;5:313–8.
Wang F, Chen M, Zhao MH. Circulating neutrophil degranulation is involved in ANCA-negative pauci-immune crescentic glomerulonephritis. J Nephrol. 2009;22:491–6.
Cong M, Chen M, Zhang JJ, Hu Z, Zhao MH. Anti-endothelial cell antibodies in antineutrophil cytoplasmic antibodies negative pauci-immune crescentic glomerulonephritis. Nephrology (Carlton). 2008;13:228–34.
Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev. 2001;180:35–48.
Schulze M, Pruchno CJ, Burns M, Baker PJ, Johnson RJ, Couser WG. Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol. 1993;142:179–87.
Chakravarti DN, Campbell RD, Porter RR. The chemical structure of the C4d fragment of the human complement component C4. Mol Immunol. 1987;24:1187–97.
Hisano S, Matsushita M, Fujita T, Endo Y, Takebayashi S. Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis. 2001;38:1082–88.
Matsushita M, Fujita T. Ficolins and the lectin complement pathway. Immunol Rev. 2001;180:78–85.
Dahl MR, Thiel M, Matsushita T, Fujita T, Willis A, Christensen T, et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity. 2001;15:127–35.
Matsushita M, Endo Y, Fujita T. Complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol. 2000;164:2281–4.
Roos A, Rastaldi MP, Calvaresi N. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17:1724–34.
Nauta AJ, Raaschou-Jensen N, Roos A, Daha MR, Madsen HO, Borrias-Essers MC, et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol. 2003;33:2853–63.
Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18:1046–56.
Cohen D, Koopmans M, Kremer Hovinga IC, Berger SP, van Roos Groningen M, Steup-Beekman GM, et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum. 2008;58:2460–9.
Ohsawa I, Ohi H, Endo M, Fujita T, Matsushita M, Fujita T. Evidence of lectin complement pathway activation in poststreptococcal glomerulonephritis. Kidney Int. 1999;56:1158–60.
Hisano S, Matsushita M, Fujita T, Iwasaki H. Activation of the lectin complement pathway in Henoch–Schonlein purpura nephritis. Am J Kidney Dis. 2005;45:295–302.
European Vasculitis Study Group (EUVAS), de Lind Van Wijngaarden RAF, Hauer HA, Wolterbeek R, Jayne DRW, Rasmussen GN, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17:2264–74.
Seelen MA, Roos A, Daha MR. Role of complement in innate and autoimmunity. J Nephrol. 2005;18:642–53.
Acknowledgments
This study is supported by a grant from National Science Fund for Distinguished Young Scholars (No.30725034) and a grant of the National Natural Science Fund (No.30972733).
We are very grateful to Dr. Wan-zhong Zou and Dr. Su-xia Wang in the Department of Pathology for assistance in collecting pathologic data of the patients.
Conflict of interests
None declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xing, Gq., Chen, M., Liu, G. et al. Differential Deposition of C4d and MBL in Glomeruli of Patients with ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis. J Clin Immunol 30, 144–156 (2010). https://doi.org/10.1007/s10875-009-9344-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-009-9344-2